اعتبار، پاسخ، و تفاوت های مهم حداقل برای مقیاس بهداشت و درمان SF-6D در جمعیت جانبازان قطع نخاع
|کد مقاله||سال انتشار||تعداد صفحات مقاله انگلیسی||ترجمه فارسی|
|10615||2008||9 صفحه PDF||سفارش دهید|
نسخه انگلیسی مقاله همین الان قابل دانلود است.
هزینه ترجمه مقاله بر اساس تعداد کلمات مقاله انگلیسی محاسبه می شود.
این مقاله تقریباً شامل 5359 کلمه می باشد.
هزینه ترجمه مقاله توسط مترجمان با تجربه، طبق جدول زیر محاسبه می شود:
Publisher : Elsevier - Science Direct (الزویر - ساینس دایرکت)
Journal : Value in Health, Volume 11, Issue 4, July–August 2008, Pages 680–688
Objective To determine the feasibility, acceptability, discriminative validity, responsiveness, and minimal important difference (MID) of the SF-6D for people with spinal cord injury (SCI). Methods A total of 305 people with SCI completed the SF-36 health status questionnaire at baseline and at subsequent occurrence of a urinary tract infection (UTI) or 6-month follow-up. Normative SF-36 data were obtained from the Australian Bureau of Statistics. SF-36 scores were transformed to SF-6D utility values using Brazier's algorithm. We used UTI as the external criterion of clinically important change to determine responsiveness and two categories of the SF-36 transition question (“somewhat worse” and “somewhat better”) as the external criterion to determine the MID. Derived SF-12 responsiveness was also assessed. Results The mean SF-6D values were: 0.68 (SD 0.21, n = 305) all patients; 0.66 (SD 0.19, n = 167) tetraplegia; 0.72 (SD 0.26, n = 138) paraplegia; 0.57 (SD 0.15, n = 138) with UTI. The Australian normative SF-6D mean value was 0.80 (SD 0.14, n = 18,005). The SF-6D was able to discriminate between SCI and the Australian normative sample (effect size [ES] = 0.86), tetraplegia–paraplegia (ES = 0.23), and it was responsive to UTI (ES = 0.86 SF-36 variant, ES = 0.92 SF-12 variant). The MID for respondents who reported being somewhat worse or somewhat better at follow-up was 0.03 (SD 0.17, n = 108/305), while the MID for only those who were somewhat worse was 0.10 (SD 0.14, n = 58). Conclusions The content of the SF-6D is more appropriate than that of the SF-36 for this physically impaired population. The SF-6D has discriminative power and is responsive to clinically important change because of UTI. The MID is consistent with published estimates for other disease groups.
Preference-based measures of health allow the relative value of health states to be compared, both within and across diseases . A fundamental concept underpinning this is health utility , a measure of preference for health outcomes. Combined with survival data, utilities can be used to estimate quality-adjusted lifeyears (QALYs). Utilities and QALYs are used in costutility analyses to assess the relative value of health interventions, across a range of purposes (preventive, diagnostic, curative, palliative), types (programs, services, technologies, pharmaceuticals), and populations (within and across diseased, disabled, and healthy populations). Preference-based measures are therefore useful and important outcome measures for policymakers, both locally and internationally. The SF-6D, a relatively new utility measure, is particularly attractive as it is calculated from the SF-36, a health status measure commonly used to assess the impact of disease and disability, including spinal injury . In common with other multiattribute utility instruments such as EQ-5D (Euroqol) and Health Utilities Index (HUI) , it allows those experiencing the health states to contribute directly to utility scores. A particular advantage of the SF-36 and SF-6D is that they economize on data collection, yielding measures of both health status and utility. Since the SF-6D methodology was published 5 years ago, it has rapidly become a popular method of utility estimation. A recent systematic review of the use of heath status measurement instruments to calculate QALYs foundthat, despite its contemporary origin, the SF-6D accounted for 5% of the instruments used . The SF-6D is a utility measure based on a sixdimensional health state classification. It is derived from a subset of 11 SF-36 questions covering the dimensions of Physical Functioning, Role Limitation, Social Functioning, Pain, Mental Health, and Vitality. It allows a possible 18,000 health states to be defined. A survey (involving SF-6D, ranking, and standard gamble) of 249 health states defined by the SF-6D was valued by a representative sample of the UK general public (n = 611). Econometric methods were then used to determine a model for predicting the standard gamble scores generated by the valuation survey . Brazier et al. have shown that the SF-6D is a viable alternative preference measure . It can be derived from either the SF-36  or the shorter SF-12 . It has been suggested that the SF-6D may be more sensitive than the EQ-5D, especially for mild–moderate health issues . Limitations and outstanding issues with the SF-6D include whether it compromises the richness of the original SF-36  and whether it is less sensitive when used in poorer health states [6,8,9]. It is therefore important that additional validation studies are performed in different populations and settings. The present article describes such a validation in an Australian population with spinal cord injury (SCI), most of whom were living in a general community setting. The minimal important difference (MID) allows clinicians to determine whether a change observed on a self-reported health rating scale is meaningful or trivial. It has been defined as the smallest difference in score that the patient perceives as beneficial . For our purposes, in the absence of significant side effects or cost barriers, this would lead to a change in clinical decision-making. This article provides the first validation and MID values for the SF-6D in the SCI population. We assess the acceptability and appropriateness of the SF-6D for application in SCI, evaluate its discriminative ability, and determine its responsiveness to clinically important change. The external criterion used to define clinically important change is the occurrence of a urinary tract infection (UTI), a common comorbidity in this patient population group, with a reported incidence of 1.82 episodes per annum [11,12].
نتیجه گیری انگلیسی
The SF-6D can reliably discriminate not only the gross differences between persons with SCI and a normative population group, but also the smaller and more clinically relevant differences between patients with paraplegia and tetraplegia. The SF-12 and SF-36 variants of the SF-6D are both responsive to the additional disease burden of UTI in this patient group. The MID is consistent with published estimates for other disease groups. The content of the SF-6D makes it more appropriate than the SF-36 for use in this physically impaired population.